100 related articles for article (PubMed ID: 15023532)
21. Monomeric and oligomeric flavanols are agonists of membrane androgen receptors.
Nifli AP; Bosson-Kouamé A; Papadopoulou N; Kogia C; Kampa M; Castagnino C; Stournaras C; Vercauteren J; Castanas E
Exp Cell Res; 2005 Oct; 309(2):329-39. PubMed ID: 16038899
[TBL] [Abstract][Full Text] [Related]
22. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
Kampa M; Nifli AP; Charalampopoulos I; Alexaki VI; Theodoropoulos PA; Stathopoulos EN; Gravanis A; Castanas E
Exp Cell Res; 2005 Jul; 307(1):41-51. PubMed ID: 15922725
[TBL] [Abstract][Full Text] [Related]
23. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
25. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors.
Kampa M; Bakogeorgou E; Hatzoglou A; Damianaki A; Martin PM; Castanas E
Eur J Pharmacol; 1997 Sep; 335(2-3):255-65. PubMed ID: 9369381
[TBL] [Abstract][Full Text] [Related]
26. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
27. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
Nicotera TM; Schuster DP; Bourhim M; Chadha K; Klaich G; Corral DA
Prostate; 2009 Sep; 69(12):1270-80. PubMed ID: 19475654
[TBL] [Abstract][Full Text] [Related]
28. Opioids modulate constitutive B-lymphocyte secretion.
Vassou D; Bakogeorgou E; Kampa M; Dimitriou H; Hatzoglou A; Castanas E
Int Immunopharmacol; 2008 May; 8(5):634-44. PubMed ID: 18387505
[TBL] [Abstract][Full Text] [Related]
29. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Slack JK; Adams RB; Rovin JD; Bissonette EA; Stoker CE; Parsons JT
Oncogene; 2001 Mar; 20(10):1152-63. PubMed ID: 11313859
[TBL] [Abstract][Full Text] [Related]
30. Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells.
Kallergi G; Agelaki S; Markomanolaki H; Georgoulias V; Stournaras C
Cell Physiol Biochem; 2007; 20(6):977-86. PubMed ID: 17982280
[TBL] [Abstract][Full Text] [Related]
31. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism.
Franzen CA; Amargo E; Todorović V; Desai BV; Huda S; Mirzoeva S; Chiu K; Grzybowski BA; Chew TL; Green KJ; Pelling JC
Cancer Prev Res (Phila); 2009 Sep; 2(9):830-41. PubMed ID: 19737984
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
34. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
35. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.
Sainz RM; Mayo JC; Tan DX; León J; Manchester L; Reiter RJ
Prostate; 2005 Apr; 63(1):29-43. PubMed ID: 15378522
[TBL] [Abstract][Full Text] [Related]
36. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
37. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
38. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway.
Zheng DQ; Woodard AS; Fornaro M; Tallini G; Languino LR
Cancer Res; 1999 Apr; 59(7):1655-64. PubMed ID: 10197643
[TBL] [Abstract][Full Text] [Related]
39. Transactivation of the epidermal growth factor receptor mediates muscarinic stimulation of focal adhesion kinase in intestinal epithelial cells.
Calandrella SO; Barrett KE; Keely SJ
J Cell Physiol; 2005 Apr; 203(1):103-10. PubMed ID: 15389641
[TBL] [Abstract][Full Text] [Related]
40. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP.
Zhang Z; Zhao Y; Batres Y; Lin MF; Ying SY
Biochem Biophys Res Commun; 1997 May; 234(2):362-5. PubMed ID: 9177276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
